SLC5A2 and type 2 diabetes mellitus: We excluded patients with a history of cardiovascular disease, because forsecondary prevention in patients with established cardiovascular disease, detaileddrug-specific recommendations (eg, SGLT2 inhibitors for congestive heart failureprevention in people with T2D) are often recommended rather than simple biomarkercontrol.38 Second, ourestimations are limited by the projection accuracy of the BRAVO simulation model.